# Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial

> **NCT07396155** · PHASE1,PHASE2 · RECRUITING · sponsor: **PT. Prodia Stem Cell Indonesia** · enrollment: 10 (estimated)

## Conditions studied

- Diabetic Nephropathy Type 2

## Interventions

- **BIOLOGICAL:** Umbilical Cord Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT07396155
- **Lead sponsor:** PT. Prodia Stem Cell Indonesia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07
- **Final completion:** 2027-10
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07396155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07396155, "Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07396155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*